A Study of Botulinum Toxin A for Ultraviolet-Induced Hyperpigmentation: A Randomized Controlled Trial

Area of Science:

• Dermatology
• Aesthetics

Background:

• Ultraviolet (UV) radiation is a primary cause of skin hyperpigmentation.
• Botulinum neurotoxin type A (BoNT-A) has demonstrated potential in mitigating UVB-induced hyperpigmentation in preclinical models.

Purpose of the Study:

• To evaluate the efficacy of intradermal BoNT-A injections in preventing UVB-induced hyperpigmentation in human participants.
• To assess the protective effect of varying BoNT-A concentrations against UV-induced skin darkening.

Main Methods:

• A prospective, double-blinded, randomized controlled trial involving 15 healthy individuals.
• Intradermal injections of different BoNT-A dilutions and saline were administered to abdominal sites.
• UVB irradiation was applied to induce hyperpigmentation, followed by assessments of lightness index and hyperpigmentation scores.

Main Results:

• All BoNT-A treated sites showed significantly reduced hyperpigmentation compared to the control group one week post-UVB exposure (p < .05).
• No significant differences in efficacy were found among the tested BoNT-A concentrations.
• No adverse side effects were reported during the study.

Conclusions:

• Intradermal BoNT-A administration offers a protective effect against UVB-induced skin hyperpigmentation.
• BoNT-A may hold therapeutic potential for managing hyperpigmentation disorders exacerbated by UV exposure.